2021 Fiscal Year Final Research Report
Development of a new targeted anticancer treatment for Adolescent and Young Adult refractory soft tissue sarcoma
Project/Area Number |
19K07753
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 50020:Tumor diagnostics and therapeutics-related
|
Research Institution | Sapporo Medical University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
加藤 淳二 札幌医科大学, 医学部, 教授 (20244345)
高田 弘一 札幌医科大学, 医学部, 講師 (90398321)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | 難治性軟部肉腫 / 標的抗がん治療法 |
Outline of Final Research Achievements |
Development of a new treatment method is desired to improve the prognosis of advanced soft tissue sarcoma, which is a problem in the Adolescent and Young Adult generation. In this study, we investigated the BH3 profiling and drug delivery system to clarify the anticancer drug susceptibility by a new reagent to soft tissue sarcoma using liposome bound with Fluorodeoxyglucose (FDG). This clarified the therapeutic and synergistic effects of various anticancer agents in soft tissue sarcoma.
|
Free Research Field |
臨床腫瘍
|
Academic Significance and Societal Importance of the Research Achievements |
AYA世代で問題となる進行軟部肉腫の予後改善のため、新規治療法の開発が望まれている。本研究で検討したFluorodeoxyglucose (FDG)を結合したLiposomeを使用した軟部肉腫に対する新たなDDSは、軟部肉腫における新規治療法の可能性があるが、更なる改良・検討を要する課題であった。
|